The only patient in the cohort with loss of PBRM1 (poly bromo-1) expression showed a distinct profile: a highly histopathological aggressive tumor with a marked angiogenic profile (VEGF overexpression and immature vascular stroma type 2), no PD1 or PDL1 expression, and WT status of the VHL gene. This evidence concerns the gene VEGFA and neoplasm.